West Pharmaceutical Services delivered a first quarter that exceeded Wall Street's expectations, driven by robust demand for its high-value product (HVP) components and operational improvements in its manufacturing facilities. Management credited the strong results to accelerated growth in both GLP-1 and non-GLP-1 HVP components, with CEO Eric Green pointing to the “tremendous execution of our operating unit strategy” and increased output, particularly in Europe. The company also saw notable momentum in its biologics business, as well as successful capacity ramp-ups that helped meet heightened demand.
Is now the time to buy WST? Find out in our full research report (it’s free for active Edge members).
West Pharmaceutical Services (WST) Q1 CY2026 Highlights:
- Revenue: $844.9 million vs analyst estimates of $779.1 million (21% year-on-year growth, 8.4% beat)
- Adjusted EPS: $2.13 vs analyst estimates of $1.68 (27.1% beat)
- Adjusted EBITDA: $226.2 million vs analyst estimates of $190 million (26.8% margin, 19.1% beat)
- The company lifted its revenue guidance for the full year to $3.32 billion at the midpoint from $3.25 billion, a 2.4% increase
- Management raised its full-year Adjusted EPS guidance to $8.58 at the midpoint, a 6.9% increase
- Operating Margin: 21%, up from 15.3% in the same quarter last year
- Market Capitalization: $20.87 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From West Pharmaceutical Services’s Q1 Earnings Call
-
Patrick Donnelly (Citi) asked about the drivers behind non-GLP-1 HVP growth. CEO Eric Green pointed to increasing market demand in biologics and biosimilars, strong commercialized drug momentum, and regulatory upgrades.
-
Michael Ryskin (Bank of America) questioned whether the Middle East crisis led to prebuying or unusual order patterns. CFO Robert McMahon clarified that no pull-forward was observed and any SmartDose revenue surge was tied to the anticipated transaction, not geopolitical events.
-
Paul Knight (KeyBanc) inquired about bottlenecks and the speed of customer site qualification. Green explained that capacity expansion and multi-site qualifications are underway, with transfer and validation taking 6–12 months.
-
Kallum Titchmarsh (Morgan Stanley) asked about the duration and breadth of Annex 1 upgrades. Green noted growing customer engagement globally, with early momentum in the U.S. and Asia supporting a multi-year tailwind.
-
Justin Bowers (Deutsche Bank) sought updates on Dublin facility demand and GLP-1 indications beyond diabetes and obesity. Green confirmed new customer contracts and a robust pipeline for additional GLP-1 indications and combination molecules.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will be watching (1) the pace of HVP conversion and Annex 1-driven upgrades across global markets, (2) the execution of operational improvements and capacity expansions at manufacturing sites, and (3) the progression of the West Vantage segment’s shift toward higher-margin drug handling services. Additionally, developments in GLP-1 adoption and biosimilar launches could further shape the company’s growth trajectory.
West Pharmaceutical Services currently trades at $295.22, up from $274.41 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
